These are top 10 stocks traded on the Robinhood UK platform in July
Inspire Medical Systems, Inc. (NYSE:INSP), a $5.3 billion medical devices company with strong revenue growth of 28.5% over the last twelve months, has seen significant insider activity, as Randy Ban, the Executive Vice President of Patient Access and Therapy Development, executed a series of stock transactions recently. According to InvestingPro analysis, the company maintains a GREAT financial health score.
On February 13, Ban sold a substantial number of shares, amounting to a total value of approximately $4.69 million. The shares were sold at prices ranging from $178.54 to $187.66, according to the latest SEC filing.
In addition to the sales, Ban acquired 25,000 shares through stock options at an exercise price of $67.63 per share, totaling around $1.69 million. These transactions were part of a 10b5-1 trading plan adopted by Ban in November 2024.
Following these transactions, Ban’s direct ownership stands at 7,259 shares. The activity reflects a strategic rebalancing of his holdings in the company, which specializes in surgical and medical instruments. The company operates with minimal debt (Debt/Equity ratio of 0.05) and maintains excellent liquidity with a current ratio of 7.13, demonstrating strong financial management.
In other recent news, Inspire Medical Systems has been the focus of several analyst assessments following its fourth-quarter results for 2024. UBS reaffirmed their Buy rating on Inspire Medical (TASE:PMCN), setting a price target of $265, noting the company’s robust fundamentals and continued growth potential. RBC Capital Markets maintained an Outperform rating for Inspire Medical with a $260 target, emphasizing the company’s operational excellence and profitability.
Despite a Department of Justice investigation, analysts from both UBS and RBC Capital Markets view any resultant dip in share price as a compelling buying opportunity given the company’s financial health. Truist Securities, while lowering its price target for Inspire Medical to $235, also retained a Buy rating, suggesting the ongoing legal scrutiny will not significantly impact the company’s long-term prospects.
Meanwhile, Morgan Stanley (NYSE:MS) reduced its price target from $230 to $220 but continued to endorse the stock with an Overweight rating. The firm sees the company’s guidance as conservative, indicating room for positive performance. Lastly, Piper Sandler reiterated an Overweight rating on Inspire Medical with a $233 target, highlighting the strength in the company’s profit despite the DOJ investigation. These assessments suggest a generally positive outlook for Inspire Medical’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.